Caroline J Breitbach
Overview
Explore the profile of Caroline J Breitbach including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
3034
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shearer T, Comstock M, Williams Jr R, Johnson M, Cendrowicz E, Leonowens C, et al.
Cancer Res Commun
. 2024 Nov;
4(12):3114-3123.
PMID: 39530736
GSIs can enhance multiple myeloma therapies targeting BCMA by increasing mbBCMA on plasma cells. In response to the GSI nirogacestat, mbBCMA rapidly and robustly increased in vitro and in vivo....
2.
Crupi M, Taha Z, Janssen T, Petryk J, Boulton S, Alluqmani N, et al.
Front Immunol
. 2022 Nov;
13:1029269.
PMID: 36405739
Colorectal cancer is the third most diagnosed cancer and the second leading cause of cancer mortality worldwide, highlighting an urgent need for new therapeutic options and combination strategies for patients....
3.
Breitbach C
Methods Mol Biol
. 2019 Sep;
2058:285-293.
PMID: 31486046
Oncolytic viral immunotherapy based on the MG1 Maraba platform has undergone extensive preclinical evaluation, resulting in the advancement of two programs into clinical trials. MG1 Maraba encoding tumor antigens (tumor...
4.
Pol J, Acuna S, Yadollahi B, Tang N, Stephenson K, Atherton M, et al.
Oncoimmunology
. 2018 Dec;
8(1):e1512329.
PMID: 30546947
Multiple immunotherapeutics have been approved for cancer patients, however advanced solid tumors are frequently refractory to treatment. We evaluated the safety and immunogenicity of a vaccination approach with multimodal oncolytic...
5.
Pol J, Atherton M, Bridle B, Stephenson K, Le Boeuf F, Hummel J, et al.
Oncolytic Virother
. 2018 Dec;
7:117-128.
PMID: 30538968
Oncolytic activity of the MG1 strain of the Maraba vesiculovirus has proven efficacy in numerous preclinical cancer models, and relied not only on a direct cytotoxicity but also on the...
6.
Kim M, Nitschke M, Sennino B, Murer P, Schriver B, Bell A, et al.
Cancer Res
. 2017 Dec;
78(4):922-937.
PMID: 29259007
Oncolytic viruses pose many questions in their use in cancer therapy. In this study, we assessed the potential of mpJX-594 (mouse-prototype JX-594), a replication-competent vaccinia virus administered by intravenous injection,...
7.
Breitbach C, Bell J, Hwang T, Kirn D, Burke J
Oncolytic Virother
. 2016 Aug;
4:25-31.
PMID: 27512667
Oncolytic immunotherapeutics (OIs) are viruses designed to preferentially replicate in and lyse cancer cells, thereby triggering antitumor immunity. Numerous oncolytic platforms are currently in clinical development. Here we review preclinical...
8.
Breitbach C, Lichty B, Bell J
EBioMedicine
. 2016 Jul;
9:31-36.
PMID: 27407036
Oncolytic viruses (OV) are replicating viral therapeutics for the treatment of cancer and have been in laboratory development for about twenty years. Recently, the FDA approved Imlygic, a herpes virus...
9.
Downs-Canner S, Guo Z, Ravindranathan R, Breitbach C, OMalley M, Jones H, et al.
Mol Ther
. 2016 May;
24(8):1492-501.
PMID: 27203445
We have conducted a phase 1 study of intravenous vvDD, a Western Reserve strain oncolytic vaccinia virus, on 11 patients with standard treatment-refractory advanced colorectal or other solid cancers. The...
10.
Arulanandam R, Batenchuk C, Angarita F, Ottolino-Perry K, Cousineau S, Mottashed A, et al.
Cancer Cell
. 2015 Jul;
28(2):210-24.
PMID: 26212250
Oncolytic viruses designed to attack malignant cells can in addition infect and destroy tumor vascular endothelial cells. We show here that this expanded tropism of oncolytic vaccinia virus to the...